RE:RE:RE:Insider activity The plan was supposed to incorporate shareholder communication, during the chat with Ed Nash Paul revealed few important details such as they will dose first patient for NASH in September, they don't see any issues with the agencies, Tesamorelin might not be the first drug for the condition but the best, as they don't have the sale force capable of commercializing the drug they might partner with others so after all those encouraging news we didn't see any response from the market, still depressed valuation and volume.
So the message either was not heard by many and/or believed.
Whichever scenario the issue needs to be addressed so going forward when and if they announce encouraging news they get a positive reaction. I believe they need to speed up re-engineering as not to get a single question during the ER and with trading sessions with only few k shares are serious issues not to mention embarrassing..
qwerty22 wrote: Nothing has happened commercially, clinically, scientifically or financially since the AGM, it may not happen until late summer.
Bucknelly21 wrote: It appears that the new plan to get people interested is not taking shape in the way that we thought